Xenetic Biosciences appoints Curtis A. Lockshin as CSO
Dr. Lockshin served as the Vice President of Research and Operations of the Company since March 2014.
From July 2015 to July 2016, he served as Chief Executive Officer and Director of SciVac Therapeutics Inc., and its subsidiary SciVac, Ltd., a commercial-stage biologics and vaccine company in Rehovot, Israel, where he had been serving as CEO and Director since September 2014.
Subsequent to SciVac Therapeutics’ merger with VBI Vaccines, Inc. in July 2016, Dr. Lockshin served as Chief Technical Officer of VBI Vaccines and its subsidiary SciVac Ltd.
In addition, he has served as President and CEO of Guardum Pharmaceuticals and previously as Vice President of Corporate R&D Initiatives for OPKO Health.
Dr. Lockshin has served as a member of the Board of Directors at a number of companies including RXi Pharmaceuticals, Corp., ChromaDex, Inc., and Sorrento Therapeutics, Inc., as well as the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation.
Dr. Lockshin received his S.B. degree in Life Sciences and his Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology. ■
LATEST MOVES FROM Massachusetts
- Abpro appoints Gavin MacBeath as CSO
- bluebird bio appoints two executives
- Biogen appoints Anirvan Ghosh as SVP
- Brightcove adds Diane Hessan to board
- Biostage promotes Saverio La Francesca to president
More inside POST